Cross-sectional baseline analysis of electrocardiography in a large cohort of patients with untreated Fabry disease

Journal of Inherited Metabolic Disease

Volumn 36, Issue 5, 2013, Pages 873-879

  Niemann, Markus ^a,b   Hartmann, Tanja ^a   Namdar, Mehdi ^c   Breunig, Frank ^a   Beer, Meinrad ^a   Machann, Wolfram ^a   Herrmann, Sebastian ^a,b   Ertl, Georg ^a,b   Wanner, Christoph ^a,b   Weidemann, Frank ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c Heart Rhythm Management Centre   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE;

ADULT; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR SYSTEM EXAMINATION; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; ELECTROCARDIOGRAPHY; FABRY DISEASE; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HUMAN; KIDNEY FAILURE; LEFT VENTRICULAR SOKOLOW INDEX; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; P WAVE; PULSE RATE; QRS COMPLEX; QT DISPERSION; QT INTERVAL; REST; SEX DIFFERENCE; ST SEGMENT ELEVATION; T WAVE; ULTRASOUND SCANNER;

ADULT; CARDIOMYOPATHIES; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FABRY DISEASE; FEMALE; HEART VENTRICLES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE;

EID: 84884354847     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-012-9540-8     Document Type: Article

References (27)

1. Alfakih K, Reid S, Jones T, Sivananthan M (2004) Assessment of ventricular function and mass by cardiac magnetic resonance imaging. Eur Radiol 10:1813-1822
2. Breunig F, Weidemann F, Beer M, et al. (2003) Fabry disease: diagnosis and treatment. Kidney Int Suppl 84:S181-S185
3. Cain PA, Ahl R, Hedstrom E, et al. (2009) Age and gender specific normal values of left ventricular mass, volume and function for gradient echo magnetic resonance imaging: a cross sectional study. BMC medical imaging 2.
4. Chimenti C, Morgante E, Tanzilli G, et al. (2008) Angina in fabry disease reflects coronary small vessel disease. Circ Heart Fail 3:161-169
5. Desnick R, Ionnou Y, Eng C (1995) Fabry disease: alpha galactosidase A deficiency. In: Scriver C, Beaudet A, Sly W, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw Hill, New York, pp 2741-2784
6. Eng CM, Banikazemi M, Gordon RE, et al. (2001) A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 3:711-722
7. Eng CM, Germain DP, Banikazemi M, et al. (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 9:539-548
8. Hughes DA, Elliott PM, Shah J, et al. (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2:153-158
9. Kampmann C, Wiethoff CM, Martin C, et al. (2002) Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy. Acta Paediatr Suppl 439:21-27
10. Linhart A, Lubanda JC, Palecek T, et al. (2001) Cardiac manifestations in Fabry disease. J Inherit Metab Dis 75-83; discussion 65.
11. Mehta J, Tuna N, Moller JH, Desnick RJ (1977) Electrocardiographic and vectorcardiographic abnormalities in Fabry's disease. Am Hear J 6:699-705
12. Mehta A, Clarke JT, Giugliani R, et al. (2009) Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet 8:548-552
13. Moon JC, Sachdev B, Elkington AG, et al. (2003) Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 23:2151-2155
14. Moon JC, Sheppard M, Reed E, Lee P, Elliott PM, Pennell DJ (2006) The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 3:479-482
15. Namdar M, Kampmann C, Steffel J, et al. (2010) PQ interval in patients with Fabry disease. Am J Cardiol 5:753-756
16. Namdar M, Steffel J, Vidovic M, et al. (2011) Electrocardiographic changes in early recognition of Fabry disease. Heart 6:485-490
17. Niemann M, Breunig F, Beer M, et al. (2010) The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy. Heart 23:1915-1919
18. Niemann M, Herrmann S, Hu K, et al. (2011) Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging 6:592-601
19. Roudebush CP, Foerster JM, Bing OH (1973) The abbreviated PR interval of Fabry's disease. N Engl J Med 7:357-358
20. Schiffmann R, Kopp JB, Austin HA 3rd, et al. (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 21:2743-2749
21. Shah JS, Hughes DA, Sachdev B, et al. (2005) Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 6:842-846
22. Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P (2009) Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med Off J Am Coll Med Genet 11:790-796
23. Weidemann F, Breunig F, Beer M, et al. (2003) Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 11:1299-1301
24. Weidemann F, Breunig F, Beer M, et al. (2005) The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 12:1221-1227
25. Weidemann F, Niemann M, Breunig F, et al. (2009) Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 4:524-529
26. Whybra C, Miebach E, Mengel E, et al. (2009) A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet Med 6:441-449
27. Xia Y, Liang Y, Kongstad O, Holm M, Olsson B, Yuan S (2005) Tpeak-Tend interval as an index of global dispersion of ventricular repolarization: evaluations using monophasic action potential mapping of the epi- and endocardium in swine. J Interv Card Electrophysiol 2:79-87